TAHO Pharma Submits New Drug Application for TAH3311
TAHO Pharmaceuticals Ltd. has made a notable move in the field of healthcare with the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311. This innovative therapy represents the world's first Apixaban Oral Dissolving Film (ODF), paving the way for a significant enhancement in anticoagulant treatment options.
Understanding the Importance of TAH3311
TAH3311 is designed to effectively deliver apixaban, a commonly prescribed anticoagulant that plays a crucial role in preventing strokes. Each year, stroke impacts millions of individuals globally, and many encounter complications such as dysphagia, which can further jeopardize their health.
The Benefits of Oral Dissolving Film
This new formulation brings forward a patient-centric approach to medication. TAH3311's oral dissolving film format simplifies the process of taking medication, particularly for stroke survivors, elderly patients, and those facing difficulties with swallowing. By providing a more accessible option, TAHO Pharma aims to enhance treatment adherence and safety.
Addressing Unmet Patient Needs
Dr. Lee, CEO of TAHO Pharmaceuticals, emphasized the significance of this NDA submission, highlighting the commitment of the company to revolutionizing patient care with advanced science. The introduction of TAH3311 has the potential to change how anticoagulant therapy is perceived and administered.
The Path Toward Market Entry
With the NDA now submitted, TAHO Pharma is taking substantial steps toward entering the U.S. market. The company is keen on pursuing global partnerships that would further accelerate the availability of this pioneering product.
The Role of Apixaban in Healthcare
Apixaban, developed alongside partners BMS and Pfizer under the name Eliquis, operates as a direct factor Xa inhibitor. This powerful anticoagulant is essential in controlling thromboembolic disorders and preventing strokes, especially in non-valvular atrial fibrillation patients. It is widely recognized for its safety profile, setting it apart in the category of novel oral anticoagulants (NOACs).
About TAHO Pharmaceuticals Ltd.
Established in 2010, TAHO Pharma is dedicated to advancing drug delivery technologies that enhance patient outcomes. Specializing in innovative oral and transdermal drug delivery systems, the company leverages its proprietary Transepithelial Delivery System (TDS) platform to ensure that medications are delivered effectively and safely. This platform not only improves release profiles but also minimizes gastrointestinal side effects, ultimately leading to better bioavailability and patient compliance.
Contact Information
For more information regarding TAHO Pharmaceuticals, individuals can reach out via phone at +886-2-2659-8515, where representatives are available to provide further assistance.
Frequently Asked Questions
What is TAH3311 and why is it significant?
TAH3311 is the world’s first Apixaban Oral Dissolving Film, offering a new way to deliver anticoagulant therapy, especially for those with swallowing difficulties.
What are the common applications of Apixaban?
Apixaban is used for stroke prevention in atrial fibrillation, treatment of deep vein thrombosis, and for individuals post-surgical procedures.
How does TAH3311 improve patient outcomes?
By providing a convenient dissolving film, it enhances adherence to treatment and reduces the risks associated with swallowing pills.
What role does TAHO Pharma play in healthcare innovation?
TAHO Pharma focuses on developing advanced drug delivery systems, significantly improving how medications are delivered and experienced by patients.
How can I learn more about TAHO Pharmaceuticals?
Interested individuals are encouraged to contact TAHO Pharma directly for detailed inquiries about their products and initiatives.
